Reduction of monoclonal antibody viscosity using interpretable machine learning

References

• Lee CH, Kang TH, Godon O, Watanabe M, Delidakis G, Gillis CM, Sterlin D, Hardy D, Cogné M, Macdonald LE, et al. Publisher correction: an engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence. Nat Commun. 2019;10(1):5031. doi:10.1038/s41467-019-13108-2.
   PubMed Web of Science ®Google Scholar
• Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol. 2019;10:10. doi:10.3389/fimmu.2019.01296.
   PubMed Web of Science ®Google Scholar
• Leabman MK, Meng YG, Kelley RF, DeForge LE, Cowan KJ, Iyer S. Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys. mAbs. 2013;5(6):896–15. doi:10.4161/mabs.26436.
   PubMed Web of Science ®Google Scholar
• The Antibody Society. Therapeutic monoclonal antibodies approved or in regulatory review. [accessed 2024 Jan 5]. www.antibodysociety.org/antibody-therapeutics-product-data
   Google Scholar
• Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci. 2004;93(6):1390–402. doi:10.1002/jps.20079.
   PubMed Web of Science ®Google Scholar
• Kingsbury JS, Saini A, Auclair SM, Fu L, Lantz MM, Halloran KT, Calero-Rubio C, Schwenger W, Airiau CY, Zhang J, et al. A single molecular descriptor to predict solution behavior of therapeutic antibodies. Sci Adv. 2023;6(32):eabb0372. doi:10.1126/sciadv.abb0372.
   Google Scholar
• Raut AS, Kalonia DS. Pharmaceutical perspective on opalescence and liquid–liquid phase separation in protein solutions. Mol Pharm. 2016;13(5):1431–1444. doi:10.1021/acs.molpharmaceut.5b00937.
   PubMedGoogle Scholar
• Shan L, Mody N, Sormani P, Rosenthal KL, Damschroder MM, Esfandiary R. Developability assessment of engineered monoclonal antibody variants with a complex self-association behavior using complementary analytical and in silico tools. Mol Pharm. 2018;15(12):5697–5710. doi:10.1021/acs.molpharmaceut.8b00867.
   PubMedGoogle Scholar
• Geoghegan JC, Fleming R, Damschroder M, Bishop SM, Sathish HA, Esfandiary R. Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering. mAbs. 2016;8(5):941–950. doi:10.1080/19420862.2016.1171444.
   PubMed Web of Science ®Google Scholar
• Rai BK, Apgar JR, Bennett EM. Low-data interpretable deep learning prediction of antibody viscosity using a biophysically meaningful representation. Sci Rep. 2023;13(1):2917. doi:10.1038/s41598-023-28841-4.
   PubMed Web of Science ®Google Scholar
• Makowski EK, Wu L, Gupta P, Tessier PM. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods. mAbs. 2021;13(1):1895540. doi:10.1080/19420862.2021.1895540.
   PubMed Web of Science ®Google Scholar
• Fernández-Quintero ML, Ljungars A, Waibl F, Greiff V, Andersen JT, Gjølberg TT, Jenkins TP, Voldborg BG, Grav LM, Kumar S, et al. Assessing developability early in the discovery process for novel biologics. mAbs. 2023;15(1):2171248. doi:10.1080/19420862.2023.2171248.
   PubMed Web of Science ®Google Scholar
• Sawant MS, Streu CN, Wu L, Tessier PM. Toward drug-like multispecific antibodies by design. Int J Mol Sci. 2020;21(20):7496. doi:10.3390/ijms21207496.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang H, Feng N, Li Y, Gu J, Wang Z. Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics. Antib Ther. 2023;6(1):13–29. doi:10.1093/abt/tbac029.
   PubMedGoogle Scholar
• Agrawal NJ, Helk B, Kumar S, Mody N, Sathish HA, Samra HS, Buck PM, Li L, Trout BL. Computational tool for the early screening of monoclonal antibodies for their viscosities. mAbs. 2016;8(1):43–48. doi:10.1080/19420862.2015.1099773.
   PubMed Web of Science ®Google Scholar
• Tomar DS, Li L, Broulidakis MP, Luksha NG, Burns CT, Singh SK, Kumar S. In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions. mAbs. 2017;9(3):476–89. doi:10.1080/19420862.2017.1285479.
   PubMed Web of Science ®Google Scholar
• Lai PK, Fernando A, Cloutier TK, Gokarn Y, Zhang J, Schwenger W, Chari R, Calero-Rubio C, Trout BL. Machine learning applied to determine the molecular descriptors responsible for the viscosity behavior of concentrated therapeutic antibodies. Mol Pharm. 2021;18(3):1167–75. doi:10.1021/acs.molpharmaceut.0c01073.
   PubMed Web of Science ®Google Scholar
• Mock M, Jacobitz AW, Langmead CJ, Sudom A, Yoo D, Humphreys SC, Alday M, Alekseychyk L, Angell N, Bi V, et al. Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies. mAbs. 2023;15(1):2256745. doi:10.1080/19420862.2023.2256745.
   PubMed Web of Science ®Google Scholar
• Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. mAbs. 2014;6(2):483–492. doi:10.4161/mabs.27431.
   PubMed Web of Science ®Google Scholar
• Wu J, Schultz JS, Weldon CL, Sule SV, Chai Q, Geng SB, Dickinson CD, Tessier PM. Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy. Protein Eng Des Sel. 2015;28(10):403–14. doi:10.1093/protein/gzv045.
   PubMed Web of Science ®Google Scholar
• Sule SV, Dickinson CD, Lu J, Chow CK, Tessier PM. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. Mol Pharm. 2013;10(4):1322–1331. doi:10.1021/mp300524x.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, et al. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc Natl Acad Sci USA. 2014;111(52):18601–06. doi:10.1073/pnas.1421779112.
   PubMed Web of Science ®Google Scholar
• Lai PK, Swan JW, Trout BL. Calculation of therapeutic antibody viscosity with coarse-grained models, hydrodynamic calculations and machine learning-based parameters. mAbs. 2021;13(1):1907882. doi:10.1080/19420862.2021.1907882.
   PubMed Web of Science ®Google Scholar
• Apgar JR, Tam ASP, Sorm R, Moesta S, King AC, Yang H, Kelleher K, Murphy D, D’Antona AM, Yan G, et al. Modeling and mitigation of high-concentration antibody viscosity through structure-based computer-aided protein design. PloS ONE. 2020;15(5):e0232713–. doi:10.1371/journal.pone.0232713.
   PubMed Web of Science ®Google Scholar
• Li L, Kumar S, Buck PM, Burns C, Lavoie J, Singh SK, Warne NW, Nichols P, Luksha N, Boardman D, et al. Concentration dependent viscosity of monoclonal antibody solutions: explaining experimental behavior in terms of molecular properties. Pharm Res. 2014;31(11):3161–3178. doi:10.1007/s11095-014-1409-0.
   PubMed Web of Science ®Google Scholar
• Yadav S, Shire SJ, Kalonia DS. Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. J Pharm Sci. 2010;99(12):4812–29. doi:10.1002/jps.22190.
   PubMed Web of Science ®Google Scholar
• Lai PK, Gallegos A, Mody N, Sathish HA, Trout BL. Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics. mAbs. 2022;14(1):2026208. doi:10.1080/19420862.2022.2026208.
   PubMed Web of Science ®Google Scholar
• Thorsteinson N, Gunn JR, Kelly K, Long W, Labute P. Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics. mAbs. 2021;13(1):1981805. doi:10.1080/19420862.2021.1981805.
   PubMed Web of Science ®Google Scholar
• Domnowski M, Lo Presti K, Binder J, Reindl J, Lehmann L, Kummer F, Wolber M, Satzger M, Dehling M, Jaehrling J, et al. Generation of mAb variants with less attractive self-interaction but preserved target binding by well-directed mutation. Mol Pharm. 2021;18(1):236–245. doi:10.1021/acs.molpharmaceut.0c00848.
   PubMedGoogle Scholar
• Perchiacca JM, Ladiwala ARA, Bhattacharya M, Tessier PM. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. Protein Eng Des Sel. 2012;25(10):591–602. doi:10.1093/protein/gzs042.
   PubMed Web of Science ®Google Scholar
• Lee CC, Julian MC, Tiller KE, Meng F, DuConge SE, Akter R, Raleigh DP, Tessier PM. Design and optimization of anti-amyloid domain antibodies specific for β-amyloid and islet amyloid polypeptide. J Biol Chem. 2016;291(6):2858–73. doi:10.1074/jbc.M115.682336.
   PubMed Web of Science ®Google Scholar
• Arbabi-Ghahroudi M, To R, Gaudette N, Hirama T, Ding W, MacKenzie R, Tanha J. Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points. Protein Eng Des Sel. 2009;22(2):59–66. doi:10.1093/protein/gzn071.
   PubMed Web of Science ®Google Scholar
• Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci USA. 2012;109(27):10879–84. doi:10.1073/pnas.1202866109.
   PubMed Web of Science ®Google Scholar
• Makowski EK, Chen H, Lambert M, Bennett EM, Eschmann NS, Zhang Y, Zupancic JM, Desai AA, Smith MD, Lou W, et al. Reduction of therapeutic antibody self-association using yeast-display selections and machine learning. mAbs. 2022;14(1):2146629. doi:10.1080/19420862.2022.2146629.
   PubMed Web of Science ®Google Scholar
• Cheng W, Joshi SB, Jain NK, He F, Kerwin BA, Volkin DB, Russell Middaugh C. Linking the solution viscosity of an IgG2 monoclonal antibody to its structure as a function of pH and temperature. J Pharm Sci. 2013;102(12):4291–304. doi:10.1002/jps.23748.
   PubMed Web of Science ®Google Scholar
• Hung JJ, Dear BJ, Dinin AK, Borwankar AU, Mehta SK, Truskett TT, Johnston KP. Improving viscosity and stability of a highly concentrated monoclonal antibody solution with concentrated proline. Pharm Res. 2018;35(7):133. doi:10.1007/s11095-018-2398-1.
   PubMed Web of Science ®Google Scholar
• Starr CG, Makowski EK, Wu L, Berg B, Kingsbury JS, Gokarn YR, Tessier PM. Ultradilute measurements of self-association for the Identification of antibodies with favorable high-concentration solution properties. Mol Pharm. 2021;18(7):2744–53. doi:10.1021/acs.molpharmaceut.1c00280.
   PubMedGoogle Scholar
• Lai PK, Ghag G, Yu Y, Juan V, Fayadat-Dilman L, Trout BL. Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: experimental assessment and computational predictions of domain interactions. mAbs. 2021;13(1):1991256. doi:10.1080/19420862.2021.1991256.
   PubMed Web of Science ®Google Scholar
• Tilegenova C, Izadi S, Yin J, Huang CS, Wu J, Ellerman D, Hymowitz SG, Walters B, Salisbury C, Carter PJ, et al. Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies. mAbs. 2020;12(1):1692764. doi:10.1080/19420862.2019.1692764.
   PubMed Web of Science ®Google Scholar
• Makowski EK, Kinnunen PC, Huang J, Wu L, Smith MD, Wang T, Desai AA, Streu CN, Zhang Y, Zupancic JM, et al. Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space. Nat Commun. 2022;13(1):3788. doi:10.1038/s41467-022-31457-3.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu L, Gupta P, Desai AA, Smith MD, Rabia LA, Ludwig SD, Tessier PM. Physicochemical rules for identifying monoclonal antibodies with drug-like specificity. Mol Pharm. 2020;17(7):2555–69. doi:10.1021/acs.molpharmaceut.0c00257.
   PubMedGoogle Scholar
• Harvey EP, Shin JE, Skiba MA, Nemeth GR, Hurley JD, Wellner A, Shaw AY, Miranda VG, Min JK, Liu CC, et al. An in silico method to assess antibody fragment polyreactivity. Nat Commun. 2022;13(1):7554. doi:10.1038/s41467-022-35276-4.
   PubMed Web of Science ®Google Scholar
• Wu SJ, Luo J, O’Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS, et al. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel. 2010;23(8):643–651. doi:10.1093/protein/gzq037.
   PubMed Web of Science ®Google Scholar
• Feng J, Jiang M, Shih J, Chai Q. Antibody apparent solubility prediction from sequence by transfer learning. iScience. 2022;25(10):105173. doi:10.1016/j.isci.2022.105173.
   PubMed Web of Science ®Google Scholar
• Wolf Pérez AM, Sormanni P, Andersen JS, Sakhnini LI, Rodriguez-Leon I, Bjelke JR, Gajhede AJ, De Maria L, Otzen DE, Vendruscolo M, et al. In vitro and in silico assessment of the developability of a designed monoclonal antibody library. mAbs. 2019;11(2):388–400. doi:10.1080/19420862.2018.1556082.
   PubMed Web of Science ®Google Scholar
• Ahmed L, Gupta P, Martin KP, Scheer JM, Nixon AE, Kumar S. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics. Proc Natl Acad Sci USA. 2021;118(37):e2020577118. doi:10.1073/pnas.2020577118.
   PubMed Web of Science ®Google Scholar
• Gupta P, Makowski EK, Kumar S, Zhang Y, Scheer JM, Tessier PM. Antibodies with weakly basic isoelectric points minimize trade-offs between formulation and physiological colloidal properties. Mol Pharm. 2022;19(3):775–787. doi:10.1021/acs.molpharmaceut.1c00373.
   PubMedGoogle Scholar
• Jacobsen FW, Stevenson R, Li C, Salimi-Moosavi H, Liu L, Wen J, Luo Q, Daris K, Buck L, Miller S, et al. Engineering an IgG scaffold lacking effector function with optimized developability. J Biol Chem. 2017;292(5):1865–75. doi:10.1074/jbc.M116.748525.
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci USA. 2017;114(5):944–49. doi:10.1073/pnas.1616408114.
   PubMed Web of Science ®Google Scholar
• Makowski EK, Wang T, Zupancic JM, Huang J, Wu L, Schardt JS, De Groot AS, Elkins SL, Martin WD, Tessier PM. Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning. Nat Biomed Eng. 2024 Jan;8(1):45–56. doi:10.1038/s41551-023-01074-6.
   Google Scholar
• Eisenberg D, Weiss RM, Terwilliger TC. The hydrophobic moment detects periodicity in protein hydrophobicity. Proc Natl Acad Sci USA. 1984;81(1):140–44. doi:10.1073/pnas.81.1.140.
   PubMed Web of Science ®Google Scholar
• Dunbar J, Deane CM. ANARCI: antigen receptor numbering and receptor classification. Bioinformatics. 2016;32(2):298–300. doi:10.1093/bioinformatics/btv552.
   PubMed Web of Science ®Google Scholar
• Winters D, Chu C, Walker K. Automated two-step chromatography using an ÄKTA equipped with in-line dilution capability. J Chromatogr A. 2015;1424:51–58. doi:10.1016/j.chroma.2015.10.092.
   PubMed Web of Science ®Google Scholar